Cargando…

Kinase Inhibitors in Genetic Diseases

Over the years, several studies have shown that kinase-regulated signaling pathways are involved in the development of rare genetic diseases. The study of the mechanisms underlying the onset of these diseases has opened a possible way for the development of targeted therapies using particular kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Antona, Lucia, Amato, Rosario, Brescia, Carolina, Rocca, Valentina, Colao, Emma, Iuliano, Rodolfo, Blazer-Yost, Bonnie L., Perrotti, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048847/
https://www.ncbi.nlm.nih.gov/pubmed/36982349
http://dx.doi.org/10.3390/ijms24065276
_version_ 1785014298195525632
author D’Antona, Lucia
Amato, Rosario
Brescia, Carolina
Rocca, Valentina
Colao, Emma
Iuliano, Rodolfo
Blazer-Yost, Bonnie L.
Perrotti, Nicola
author_facet D’Antona, Lucia
Amato, Rosario
Brescia, Carolina
Rocca, Valentina
Colao, Emma
Iuliano, Rodolfo
Blazer-Yost, Bonnie L.
Perrotti, Nicola
author_sort D’Antona, Lucia
collection PubMed
description Over the years, several studies have shown that kinase-regulated signaling pathways are involved in the development of rare genetic diseases. The study of the mechanisms underlying the onset of these diseases has opened a possible way for the development of targeted therapies using particular kinase inhibitors. Some of these are currently used to treat other diseases, such as cancer. This review aims to describe the possibilities of using kinase inhibitors in genetic pathologies such as tuberous sclerosis, RASopathies, and ciliopathies, describing the various pathways involved and the possible targets already identified or currently under study.
format Online
Article
Text
id pubmed-10048847
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100488472023-03-29 Kinase Inhibitors in Genetic Diseases D’Antona, Lucia Amato, Rosario Brescia, Carolina Rocca, Valentina Colao, Emma Iuliano, Rodolfo Blazer-Yost, Bonnie L. Perrotti, Nicola Int J Mol Sci Review Over the years, several studies have shown that kinase-regulated signaling pathways are involved in the development of rare genetic diseases. The study of the mechanisms underlying the onset of these diseases has opened a possible way for the development of targeted therapies using particular kinase inhibitors. Some of these are currently used to treat other diseases, such as cancer. This review aims to describe the possibilities of using kinase inhibitors in genetic pathologies such as tuberous sclerosis, RASopathies, and ciliopathies, describing the various pathways involved and the possible targets already identified or currently under study. MDPI 2023-03-09 /pmc/articles/PMC10048847/ /pubmed/36982349 http://dx.doi.org/10.3390/ijms24065276 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
D’Antona, Lucia
Amato, Rosario
Brescia, Carolina
Rocca, Valentina
Colao, Emma
Iuliano, Rodolfo
Blazer-Yost, Bonnie L.
Perrotti, Nicola
Kinase Inhibitors in Genetic Diseases
title Kinase Inhibitors in Genetic Diseases
title_full Kinase Inhibitors in Genetic Diseases
title_fullStr Kinase Inhibitors in Genetic Diseases
title_full_unstemmed Kinase Inhibitors in Genetic Diseases
title_short Kinase Inhibitors in Genetic Diseases
title_sort kinase inhibitors in genetic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048847/
https://www.ncbi.nlm.nih.gov/pubmed/36982349
http://dx.doi.org/10.3390/ijms24065276
work_keys_str_mv AT dantonalucia kinaseinhibitorsingeneticdiseases
AT amatorosario kinaseinhibitorsingeneticdiseases
AT bresciacarolina kinaseinhibitorsingeneticdiseases
AT roccavalentina kinaseinhibitorsingeneticdiseases
AT colaoemma kinaseinhibitorsingeneticdiseases
AT iulianorodolfo kinaseinhibitorsingeneticdiseases
AT blazeryostbonniel kinaseinhibitorsingeneticdiseases
AT perrottinicola kinaseinhibitorsingeneticdiseases